Shuchi Nahar's Weekend Blog!

Healthcare Global Enterprise Ltd. -  India's Leading Oncology Focused Network Background Established in 1989, Healthcare Global Enterprises Limited (HCG), is present primarily in the oncology field with the largest cancer care network (with 22 cancer care centers as of December 2021) and three multi-specialty hospitals. It is promoted by Dr. B.S. Ajai Kumar, practicing radiation and medical oncologist with over 30 years of experience. Originally established with a single cancer care center, the Bangalore Institute of Oncology (BIO), at Bangalore by Dr. B.S. Ajai Kumar and four other oncologists, the company has rapidly expanded its presence to Ahmedabad, Chennai, Nasik, Ranchi, Rajkot, Cuttack, Hubli, Mumbai, Nagpur, Vizag, and Vijayawada, among others. The company is now present across the oncology value chain, offering services from prevention, screening, diagnosis, and treatment to rehabilitation, supportive care, and palliative care. Pursuant to the Investment Agreement enter

Syngene International Ltd. FY2020-21 Annual Report Key Takeaways  In continuation of my previous blog here is the updated version l ink to Initial Blog -  https://myweekendspot.blogspot.com/2020/10/syngene-next-giant-player-for-cdmo.html Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies.   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agrochemicals, etc. It currently caters to 400+ global players including Bristol-Myers Squibb (BMS), Abbott, Baxter, and Amgen, among others. SIL derives 95% of its revenues from exports.   Syngene continued to build on its integrated drug discovery and development portfolio during the year, including a five-year collaboration with 3DC, the drug discovery

Syngene Q4FY21 and Full Year FY21 - Result Update  Twitter Handle: @shuchi_nahar Syngene International Limited on 28 th April 2021 announced its Q4FY21 and full-year results. The Company reported quarterly revenue from operations of Rs. 659 Cr and Rs. 2,184 Cr for the full year. Underlying revenue from operations (excluding export incentives) for the quarter grew 13% compared with the same period last year and by 12% for the full year. Profit after tax (before exceptional gain) for the quarter increased by 15% year-on-year to Rs. 138 Cr, and by 4% to Rs. 382 Cr for the full year. Revenue Growth over the Years 1. Growth driven by an increase in sales from existing clients and acquisition of new clients  2. Engage, expand and extend the strategy to extend client relationship over a longer period of time  3. Growth in the total number of clients  4. Increase in average revenue from largest clients  5. Increase in number of services offered to clients The highlight of the quarter was the

Dharamsi Morarji Chemical Company - Company Overview The Dharamsi Morarji Chemical Company Limited (DMCC), established in 1919, was the first producer of Sulphuric Acid and Phosphate fertilizers in India. Over the years, the brand of the Company (“Ship”) came to be recognized as the quality standard for Single Superphosphate (SSP). Until recently, DMCC was known primarily as a fertilizer producer, with over 75% of revenue from SSP. As a strategy, DMCC structured itself to Speciality Chemicals. With focused Research and Development efforts, processes for downstream sulfur-based chemicals were commercialized. Diversified Product & Customer Base The company has 34 unique products across bulk and specialty chemicals. The company has a wide product basket that helps us in penetrating new geographies and acquiring new customers. The chemicals manufactured and applied in a wide range of industries across 25 countries. Impact on Bulk Chemicals Companies  bulk chemicals had an unfavorable m

The Stronger Conviction for CDMO's - Bright Future Ahead Twitter Handle: @shuchi_nahar 1) Laurus Labs –The Complete Turnaround Story Laurus Labs is a leading R&D driven pharmaceuticals company established in 2005 with its headquarters in Hyderabad. It is among the leaders in the manufacturing of Active Pharmaceutical Ingredients (APIs) for Antiretroviral (ARV) and Hepatitis C (Hep-C) formulations. Other major API segments include therapeutic areas such as Oncology, Cardiovascular, and Anti-Diabetes. From a one-product company in 2010 to an Active Pharmaceutical Ingredients (APIs) company thereafter, the company has now emerged as one of India’s leading manufacturers of generics APIs for various complex therapies. Revenue Comparison FY19 v/s FY20 Significant Growth in CDMO For Detailed Analysis of the above company - https://myweekendspot.blogspot.com/2020/09/laurus-labs-company-overview.html To continue reading this great compilation of CDMO Companies Click the Link :  https://

Advance Enzyme  Technologies Ltd  – Pioneers in Enzyme Biotechnology Twitter Handle: @shuchi_nahar Link: https://myweekendspot.blogspot.com/2020/12/what-are-enzyme-biotechnology-market.html Incorporated by second-generation enzymologists, the Rathi brothers in 1989, Advanced Enzyme Technologies (AET) is one of the largest research-driven Indian enzyme companies with a product basket of 400+ proprietary products developed from 68 indigenous enzymes and probiotics. Broadly, the business can be divided into three segments – 1) Human healthcare 2) Animal healthcare 3) Industrial processing. It manufactures enzymes by using natural resources such as plants, fungal, bacterial, and animal sources, using environment-friendly biotechnology processes. It offers these products to 700+ customers across 45 countries worldwide. Product Insights This classification provides break-up on the basis of the enzyme function. For example: 1) Proteases : They break down proteins (used in in